Clinical effect of Yiqi Huoxue Huatan Tongluo Decoction inthe treatment of angina pectoris(heart-blood stasis syn-drome)after PCI for coronary heart disease
Objective:To explore the clinical curative effect of Yiqi Huoxue Huatan Tongluo Decoction in recurrent angina pectoris(AP,heart-blood stasis syndrome)after percutaneous coronary intervention(PCI)for coronary heart disease.Methods:A total of 110patients with recurrent AP after PCI for coronary heart disease in the hospital were enrolled between June 2022and June 2023,and they were randomly divided into control group(routine western medicine)and experimental group(Yiqi Huoxue Huatan Tongluo Decoction on basis of control group),55cases in each group.The clinical curative effect after treatment,scores of TCM syndromes,frequency and duration of AP onset,scores of Seattle Angina Questionnaire(SAQ),blood lipid indexes[total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C)]and inflammatory indexes[high-sensitivi-ty C-reactive protein(hs-CRP),interleukin-6(IL-6),monocyte chemoattractant protein-1(MCP-1)]before and after treatment,and adverse reactions during treatment in the two groups were observed.Results:After treatment,total response rate of experimental group was higher than that of control group(94.55％vs 76.36％,P＜0.05).After treatment,scores of TCM syn-dromes in experimental group were lower than those in control group,SAQ score was higher than that in control group,frequency and duration of AP onset were lower than those in control group(P＜0.05).After treatment,TC,TG,LDL-C,hs-CRP,IL-6and MCP-1in experimental group were lower than those in control group(P＜0.05).There were no obvious adverse reactions during treatment in either group.Conclusion:Yiqi Huoxue Huatan Tongluo Decoction has good clinical curative effect in patients with recurrent AP(heart-blood stasis syndrome)after PCI for coronary heart disease,which can effectively relieve AP,reduce blood lipid and inhibit inflammatory response,with good safety.
国家科技期刊平台
NSTL
万方数据
